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We have recently confirmed that lipoteichoic acid (LTA), a major constituent of the gram-positive
bacterial surface, is the endotoxin of gram-positive bacteria that induces proinflammatory molecules in a
Toll-like receptor 2 (TLR2)-dependent manner. LTA is an anionic amphipath whose physicochemical
properties are similar to those of lipopolysaccharide (LPS), which is found on the outer leaflet of the outer
membranes of gram-negative organisms. Hypothesizing that compounds that sequester LPS could also
bind to and inhibit LTA-induced cellular activation, we screened congeneric series of polyamine sulfon-
amides which we had previously shown effectively neutralized LPS both in vitro and in animal models of
endotoxemia. We observed that these compounds do bind to and neutralize LTA, as reflected by the
inhibition of TLR2-mediated NF-B induction in reporter gene assays. Structure-activity studies showed
a clear dependence of the acyl chain length on activity against LTA in compounds with spermine and
homospermine scaffolds. We then sought to examine possible correlations between the neutralizing
potency toward LTA and antimicrobial activity in Staphylococcus aureus. A linear relationship between LTA
sequestration activity and antimicrobial activity for compounds with a spermine backbone was observed,
while all compounds with a homospermine backbone were equally active against S. aureus, regardless of
their neutralizing potency toward LTA. These results suggest that the number of protonatable charges is
a key determinant of the activity toward the membranes of gram-positive bacteria. The development of
resistance to membrane-active antibiotics has been relatively slower than that to conventional antibiotics,
and it is possible that compounds such as the acylpolyamines may be useful clinically, provided that they
have an acceptable safety profile and margin of safety. A more detailed understanding of the mechanisms
of interactions of these compounds with LPS and LTA, as well as the gram-negative and -positive bacterial
cell surfaces, will be instructive and should allow the rational design of analogues which combine
antisepsis and antibacterial properties.
Sepsis and its sequel, septic shock, a consequence of sys-
temic inflammation that leads to multiple-organ failure (32),
are common and serious clinical problems for which no specific
therapeutic options are yet available. Sepsis is the number-one
cause of death in noncardiac intensive care units (20) and
accounts for some 200,000 fatalities in the United States an-
nually (8), and the incidence continues to rise in the United
States (34) and worldwide (38), despite great strides in anti-
microbial chemotherapy.
The primary trigger in the septic shock syndrome caused
by gram-negative bacteria is thought to be endotoxin, a
constituent of the outer membrane of enterobacterial gram-
negative bacteria. Endotoxins consist of a polysaccharide
portion and a hydrophobic moiety called lipid A (Fig. 1) and
are therefore also called lipopolysaccharides (LPSs). Total
synthesis of the structurally highly conserved lipid A portion
led to the demonstration that it is the active moiety of LPS
(18, 27). Septic shock, however, is by no means an exclusive
sequel of systemic infections caused by gram-negative bac-
teria (4). Owing to the increasing prevalence of nosocomial
infections due to invasive procedures, immunosuppression,
and cancer chemotherapy, the incidence of septic shock due
to gram-positive organisms is on the rise (26, 29, 40) and is
of particular concern in individuals who have neutropenia, a
frequent attendant of ablative chemotherapy and radiother-
apy (42). Because the shock state in systemic sepsis caused
by gram-positive bacteria is clinically indistinguishable from
that caused by gram-negative bacteria (30), it has generally
been regarded that the initiation and progression of the sys-
temic inflammatory response are pathophysiologically simi-
lar, regardless of the causative organism. The prominent
role of LPS in the pathogenesis of shock caused by gram-
negative bacteria renders lipid A a logical therapeutic target
in the development of antiendotoxin strategies, and we have
made considerable progress in the structure-based design
and development of LPS sequestrants (10, 35, 39, 45). Un-
like gram-negative bacteria, which bear LPS on the outer
leaflet of the outer membrane, the external surface of the
peptidoglycan layer is decorated with lipoteichoic acids
(LTAs) (Fig. 1) in gram-positive organisms (1, 9). LTAs are
anchored in the peptidoglycan substratum via a diacylglyc-
erol moiety and bear a surface-exposed, polyanionic, 1-3-
linked polyglycerophosphate appendage (14) which varies in
its subunit composition in LTAs from various gram-positive
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bacteria; in Staphylococcus aureus, the repeating subunit
contains D-alanine and -D-N-acetylglucosamine (Fig. 1)
(17). There had been considerable disagreement as to the
identity of the endotoxin from gram-positive organisms (22–
25), but recent total syntheses of LTA species and the dem-
onstration of LPS-like activities in synthetic LTA (13, 16, 37,
46) have served to establish that LTA stimulates the pro-
duction of proinflammatory mediators. We have recently
verified that the major immunostimulatory and proinflam-
matory component(s) of the gram-positive bacterial enve-
lope in the human system is indeed LTA (28).
Because LTA, like LPS, is an anionic, amphipathic molecule
(Fig. 1) with a hydrophobic diacylglycerol moiety conjugated to
the hydrophilic and polyanionic teichoic acid (substituted
polyphosphoglycerate) appendage, it was of interest to exam-
ine if our ongoing efforts at refining polycationic amphipaths
designed to bind to and sequester LPS (10, 35, 39, 45) would
offer leads in the design of LTA-neutralizing compounds. The
hypothesis that compounds that bind to LPS as well as LTA
could be identified and refined seemed particularly plausible
since we had earlier found that certain compounds were po-
tently antibacterial against both gram-negative and gram-pos-
itive species (2), suggesting that these compounds interacted
with and destabilized the cellular envelopes of both types of
microorganisms. We now report that the proinflammatory ac-
tivities of LTA can be inhibited by sequestering LTA using
compounds previously shown to be LPS-binding and -neutral-
izing agents. The structure-activity relationships for these com-
pounds show a clear parallel between LTA- and LPS-seques-
tering activities. These results suggest that endotoxins from
both gram-negative and gram-positive bacteria may be amena-
ble to neutralization by such compounds.
MATERIALS AND METHODS
Reagents. LTA from S. aureus, extracted by the n-butanol procedure (36) and
purified by delipidation and enzymatic deproteination, was procured from Invi-
voGen (San Diego, CA). LTAs from other commercial sources were found to be
contaminated with trace quantities of Toll-like receptor 4 (TLR4)-agonistic
species (probably LPS) and were not used. Highly purified LPS isolated from
Escherichia coli O111:B4 was from List Biologicals (Campbell, CA). The synthe-
ses and characterization of the polyamine sulfonamides (Fig. 2) have been
reported earlier (5).
Cell lines. HEK-Blue-4 cells (HEK293 cells stably transfected with TLR4,
MD2, and CD14, as well as secreted alkaline phosphatase [sAP] under the
control of a promoter inducible by NF-B and activator protein 1 [AP-1]) and
HEK-Blue-2 cells (HEK293 cells stably transfected with TLR2, MD2, CD14,
and sAP, also under the control of a promoter inducible by NF-B and AP-1)
were from InvivoGen and were maintained in HEK-Blue selection medium
containing zeocin, blasticidin, and normocin, according to the vendor-sup-
plied protocols.
NF-B induction. The induction of NF-B was quantified with HEK-Blue
cells, as reported earlier (28). The stable expression of sAP under the control of
NF-B and AP-1 promoters is inducible by the occupancy of TLR2 (LTA) or
TLR4 (LPS), and the amount of extracellular sAP in the supernatant is propor-
tional to the level of NF-B induction. HEK-Blue-2 or KEK-Blue-4 cells were
FIG. 1. Structures of LTA and LPS showing physicochemical similarities (anionic amphipathic molecules).
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incubated at a density of 105 cells/ml in a volume of 80 l/well in 384-well,
flat-bottomed, cell culture-treated microtiter plates until confluence was
achieved, and the cells were subsequently treated with graded concentrations of
stimuli. sAP was assayed spectrophotometrically by using an AP-specific chro-
mogen (which is present in the HEK detection medium supplied by the vendor)
at 620 nm.
Bacterial strains and determination of MICs. E. coli strain 9637 and S. aureus
strain ATCC 13709 were procured from ATCC (Manassas, VA). These two
model organisms were chosen since their antimicrobial susceptibilities show a
high degree of overlap with those of a panel of clinical isolates that we had
examined earlier (31). The MICs of the polyamine sulfonamides were deter-
mined by the broth microdilution method, as reported previously (2). Mid-log-
phase Mueller-Hinton broth (non-cation-supplemented) cultures of organisms
(40 l; the optical density at 600 nm was adjusted to 0.5 absorbance units and the
broth was diluted 10-fold) were added to equal volumes of 2-fold serially diluted
compounds in a 384-well microtiter plate with a Biotek Precision 2000 automated
microplate pipetting system. The microtiter plates were incubated overnight at
37°C, and the absorbance at 600 nm was read. The lowest concentration that
resulted in the complete inhibition of the growth of organism was recorded as
the MIC.
RESULTS AND DISCUSSION
Confirmation of TLR2-dependent proinflammatory activity
of LTA. LTA is a TLR2 agonist, while LPS binds to TLR4.
Since we have demonstrated that several members of the acyl-
polyamine class bind to and neutralize LPS (5–7, 35), it was of
particular importance to examine in reporter gene assays the
LTA-binding and -neutralizing activities of the polyamine sul-
fonamides which respond to TLR2 while obviating the false-
positive and spurious results that arise due to contamination
with trace quantities of LPS, which is a common problem (19).
Therefore, we first verified that the LTA used was free of
endotoxin by examining the NF-B induction potency in the
HEK-Blue-4 cell assay. LTA purchased from Sigma showed
significant TLR4 agonistic activity (data not shown), presum-
ably due to LPS contamination, and was therefore excluded
from all further experiments. Purified LTA (from InvivoGen)
isolated by the n-butanol procedure, however, was devoid of
detectable LPS at concentrations of up to 10 g/ml (Fig. 3A).
We further verified that the TLR2-agonistic activities of LTA
were not inhibited in the HEK-Blue-2 assay by polymyxin B, a
specific LPS sequestrant (3, 11), even at a concentration of 2.5
mM (data not shown). It is important to note that whereas the
positive control, polymyxin B, does not inhibit LTA-induced
NF-B activation in TLR2 reporter cells, the sulfonamides
retain comparable activities in both systems. In the NF-B
induction assay with TLR2-expressing cells, LTA but not LPS
was active (Fig. 2B). We have recently demonstrated that LTA,
but not lipopeptides or peptidoglycan, induces p38 mitogen-
activated protein kinase phosphorylation, CD11b expression,
and cytokine and chemokine release in human blood in a
manner similar to that of LPS (28). Collectively, these data
confirmed that LTA is the predominant proinflammatory cy-
tokine-inducing TLR2 agonist in human blood ex vivo and may
therefore be a valid target for neutralization.
The LTA-sequestering activity, as reflected by inhibition
of TLR2-mediated NF-B induction (Fig. 4A), showed a
clear dependence of the acyl chain length. The activities of
both series 1 (spermine backbone) and series 2 (homosper-
FIG. 2. Structures of the polyamine sulfonamides.
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mine backbone) compounds were very similar, with maximal
potency (concentration inducing a half-maximal response,
1 M) observed for the C16 analogs. As has been reported
earlier in the context of LPS-binding and -inhibitory activ-
ities (5), the series 3 compounds were much weaker in their
LTA-neutralizing activities (Fig. 4A), presumably as a con-
sequence of their much poorer aqueous solubility (5). A
substantial correlation between LTA-sequestering potency
on the one hand and LPS-neutralizing activity on the other
was observed (Fig. 4B), suggesting that the interaction of
these polycationic amphipathic compounds with both LTA
and LPS occurs via electrostatic interactions stabilized by
additional hydrophobic interactions (10, 12). Although cat-
ionic peptides have been shown to bind to and abrogate the
activities of both LPS and LTA (21, 44), these results, to our
knowledge, are the first describing this phenomenon in syn-
thetic small molecules.
FIG. 4. (A) Correlation of carbon number of the acyl chain of the
polyamine sulfonamides and their LTA-inhibitory activities, as as-
sessed by the HEK-2-Blue NF-B reporter gene assay. (B) Correlation
of inhibition of LTA- and LPS-induced NF-B translocation, as mea-
sured with HEK-2-Blue and HEK-4-Blue cells, respectively. Each di-
lution was tested in quadruplicate, and experiments were repeated
three times; coefficients of variation were less than 7%, and for clarity,
only the means are shown. (C) Correlation of LTA-inhibitory activity
and activity against S. aureus strain ATCC 13709.
FIG. 3. (A) NF-B induction activity of LPS and LTA in TLR4-
expressing HEK-4-Blue cells treated overnight. sAP was measured
colorimetrically. (B) NF-B induction in TLR2-expressing HEK-2-
Blue cells treated overnight with 1:2 serially diluted concentrations of
LPS and LTA ascertained as described for panel A. Each dilution was
tested in quadruplicate; coefficients of variation were less than 3%, and
for clarity, only the means are shown.
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Certain acylpolyamines have been found to significantly
inhibit the growth of both gram-negative and gram-positive
bacteria (2), and it is therefore not surprising that these
compounds also show antimicrobial activities. We sought to
examine possible correlations between perturbations of the
LTA layer by using the potency of LTA sequestration as a
surrogate readout and activity against a prototype gram-
positive organism (S. aureus) with a view to identifying the
equivalent of polymyxin B, a peptide antibiotic known to
disrupt the supramolecular assembly of the LPS constituting
the outer membranes of gram-negative bacteria (41, 47).
While we found a quasilinear relationship between LTA-
sequestering activity and antimicrobial activity for the series
1 compounds, all series 2 compounds were equally active
against S. aureus, regardless of their ability to abrogate the
effects of LTA. An inverse relationship was observed for
the series 3 compounds (Fig. 4C). We do not yet understand
the basis for these unexpected and somewhat counterintui-
tive findings. Our preliminary hypothesis is that either the
number of protonatable charges (four in series 2 compounds
and three in series 1 compounds) or the backbone itself
(homospermine in series 2 compounds) is a key determinant
of the activity toward the membranes of gram-positive bac-
teria, which appears to be relatively independent of their
LTA-binding and -sequestering potencies. This conjecture is
supported by our observation that the lower homologues of
the series 3 bis-homospermine compounds which do show
adequate aqueous solubility (compounds 3A and 3B) also
exhibit potent antimicrobial activities (MIC for S. aureus, 1
M) while displaying very poor LTA-sequestering activity
(the concentrations inducing a half-maximal response, 60 to
110 M). The bis-acylated series 3 analogues also bear four
protonatable secondary amines with the same spacing as
those of the series 1 compounds. We are examining this
hypothesis by systematically expanding our screens to in-
clude compounds with scaffolds with different amine counts
and spacings.
A more stringent structure-activity relationship was evi-
dent in the antimicrobial activities against E. coli than S.
aureus (Fig. 5). The series 1 compounds, which had carbon
chain lengths between 12 and 18, were equipotent in their
MICs against S. aureus, whereas a distinct optimum of 16
carbons was necessary for maximal activity against E. coli
(Fig. 5, top panel). Similarly, while all series 2 compounds
were equally active against S. aureus, compounds 2C and 2D
(12 and 16 carbons, respectively) were maximally active
against E. coli (Fig. 5, middle panel). As mentioned earlier,
compounds 3A and 3B were highly inhibitory toward S.
aureus and were virtually inactive against E. coli (Fig. 5,
bottom panel).
The development of resistance to membrane-active anti-
biotics has been relatively slower than that to conventional
antibiotics, as evidenced by a resurgence in the use of poly-
myxin B and colistin (15, 33, 43, 48, 49), and it is possible
that compounds such as the acylpolyamines may be useful
clinically, provided that they have an acceptable safety pro-
file and margin of safety. The considerable in vivo data that
we have obtained on related compounds that act as LPS-
sequestering compounds for the prophylaxis of sepsis caused
by gram-negative bacteria are indeed highly encouraging
(35, 39, 45), and we are currently examining such com-
pounds in animal models of systemic infections as stand-
alone antimicrobials and as adjuncts to conventional anti-
microbial chemotherapy. A more detailed understanding of
the mechanisms of interactions of these compounds with
LPS and LTA, as well as the gram-negative and gram-pos-
itive bacterial cell surfaces, will be instructive and should
allow the rational design of analogues which combine anti-
sepsis and antibacterial properties.
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